• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • GPs

Origination: tackling the valuations conundrum

Current valuation levels are sky high and a bargain
  • Greg Gille
  • Greg Gille
  • @unquotenews
  • 08 October 2015
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

In the first instalment of our Origination Series, Greg Gille takes a look at current valuations and finds out how GPs are tackling the issue when it comes to sourcing and executing deals

Private equity has long prided itself on being able to unearth value in hidden gems. Beyond the prospect of unlocking a business's organic growth potential, the lower-than-average entry multiple has a crucial impact on the eventual returns. But judging by the pricing levels witnessed in competitive processes from the beginning of 2014, this narrative is increasingly in danger of becoming a thing of the past.

The list of European transactions valuing targets at double-digit multiples of EBITDA has kept growing in the first half of 2015, with private equity players benefiting handsomely from the market's frothiness and trade buyers' ability to deploy significant amounts of cash. Gilde Buyout Partners and Parcom Capital sold Belgian mattress producer Bekaert Textiles to Haniel in May for an estimated 10x EBITDA (which stood at €50m in the previous financial year), while, more recently, Star Capital sold German cable television operator Pepcom for €608m to competitor Tele Columbus at a similar entry multiple.

Seller's market
On the flip side, prices paid by private equity houses themselves have continued to creep up, with the latest Argos Mid-Market Index (looking at median entry multiples in European €15-500m deals), shooting up to nearly 8.5x EBITDA in the first half of the year.

Andy Currie, managing partner at advisory firm Catalyst Corporate Finance, highlights the supply/demand imbalance at play: "There is a surplus of capital over opportunities and liquidity pressure outweighs traditional business logic. If you are the owner of a business today, you have more options than you have ever had: a very competitive private equity market, a buoyant alternative credit market, increasingly sophisticated family offices and high-net-worths, and trade players that in the main have strong balance sheets."

On the sponsor side, this is compounded by the fact that leverage options remain both plentiful and cheap, enabling GPs to be more aggressive on price, while still sticking to their equity sweet spots. "There is still a fairly large amount of debt capital on the sidelines, which enables people to leverage deals at a higher rate and therefore push up the prices of assets," says Ryan McNelley, managing director at Duff & Phelps. "In the private debt markets, we see players chasing higher leverage ratios and lower rates of return for a given level of risk. To a certain extent, this has been driven by US investors seeing an opportunity in Europe and expecting a tidal wave, when it has so far turned out to be more of a trickle."

This theme of too much capital chasing too few opportunities is, of course, a major factor at play for the sponsors themselves, especially for those chasing assets in European private equity's engine room, the generalist mid-market. Mitigating rising asset prices by shifting strategies on an existing fund is often not viable, as GPs promised specific exposure to their LPs. This leaves them with the option – often encouraged by the more long-term-focused LPs – of exercising restraint and waiting for the market to settle down. "We are not quite there yet – sponsors are still optimistic that they can find good deals selectively. Whether or not that will prove to be the wisest decision is hard to ascertain. We will have to wait and see the returns in five years' time," says McNelley.

Going all in
This resonates with Charlie Johnstone, origination partner at ECI Partners – a firm that was comfortable to strike a deal believed to value UK cycling retailer Evans Cycles in excess of 10x EBITDA in May. "We've had a long-term strategy of being happy to pay the right price for quality businesses, where we can bring value to the table. The proof is in the returns and you only know that when coming out the other end," he says, before adding that careful origination is key to justifying current pricing levels. "We have got better at focusing on these companies where we can bring real value; businesses we tend to gravitate towards are the ones where our strengths and experience really resonate with the owners or the management team. Therefore, we are able to pay the full price needed to win these opportunities."

But Johnstone highlights how this committed approach, which is now more widely espoused by mid-market players, is also contributing to higher levels of competition, with a predictable impact on valuations: "What is new is that we are starting to see this behaviour from firms that did not previously exhibit it. While some GPs were previously known for hunting value and chipping prices, there has sometimes been a complete reversal in recent months where these same players are now outbidding everyone in processes. It is undeniably making things more competitive."

Catalyst's Currie has witnessed first-hand how committed sponsors can be in auction processes for the right asset: "An inflexion point in the market was when 3i bought Aspen earlier this year. They were in a competitive process, but then, relatively early in the process, they said they could complete in a week because of the work they had done upfront and the money they had spent on doing extensive due diligence." It is important to note that 3i paid 10x EBITDA for Aspen, judging by the company's 2014 results. "They had put themselves in a position where they were highly deliverable so from a seller's perspective it was not only a good price, but also low-risk because of how much work they had done."

GPs' willingness to go all in on what they perceive to be the right asset will remain a feature of the market until either the supply (attractive investment opportunities) or demand (the dry powder of both private equity players and debt providers) are affected in a significant way. In the meantime, Currie expects more of the same for the remainder of 2015: "We don't see any reasons why prices should fall, but there are equally no signs that they should get any better." Whether or not asset prices in Europe are at a peak or have simply plateaued is a different matter – the latter could prompt fund managers to rethink their approach to deal origination even more thoroughly in the longer term if they do not wish to be caught up in the arms race.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • GPs
  • Buyouts
  • Origination Series
  • Top story
  • ECI Partners
  • 3i
  • Inflexion Private Equity
  • Gilde Buy Out Partners

More on GPs

EU foreign subsidies regulations
EU FSR could impact PE fundraising with potential rise in ‘clean funds’

FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely

  • Regulation
  • 01 September 2023
Jan Cerny of BHM Group
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • Investments
  • 01 September 2023
Bettina Curtze of Redalpine
Redalpine expands leadership team amid CHF 1bn-plus fundraise

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • Venture
  • 31 August 2023
Canary Wharf and the financial centre of London
IPO offers CVC chance to become multi-asset consolidator

Potential IPO also offers monetisation solution for founders and GP stakes investor Blue Owl

  • GPs
  • 25 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013